The task force found FIT to be a low cost test that has been shown to be highly effective when repeated annually. The Company stated that they expect the InSure ONE test to be available in early 2018.

Clinical Genomics' fecal occult blood test InSure FIT was more effective than two other leading tests in a study of 1,000-plus people, according to a study published in The American Journal of ...

A recent press release by Quest Diagnostics announced a 5-year extension to their U.S. supply agreement for the InSure® ONE™ fecal immunochemical test (FIT), a test for colorectal cancer ...